Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025
Jazz Pharmaceuticals reported positive Phase 3 results for its cancer drug Ziihera in HER2-positive gastroesophageal adenocarcinoma, showing significant improvements in survival endpoints. Jazz shares surged up to 31% pre-market before settling near $141.07 by early afternoon Monday. Ziihera partner Zymeworks saw pre-market gains as high as 59%. The trial enrolled 914 patients across 30 countries.
